CVKD – cadrenal therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook [Yahoo! Finance]
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) had its price target raised by analysts at HC Wainwright from $3.00 to $32.00. They now have a "buy" rating on the stock.
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE
Form S-3 Cadrenal Therapeutics,
Form SC 13G/A Cadrenal Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
Form D Cadrenal Therapeutics,
Form 10-Q Cadrenal Therapeutics, For: Sep 30
Form 8-K Cadrenal Therapeutics, For: Nov 07
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.